Drug combination slows progression of treatment resistant bone marrow cancer

CHAPEL HILL -- Combining a newly formulated drug with one that is already a standard treatment slows the progression of multiple myeloma, an advanced cancer of the bone marrow cells, according to a clinical trial led by a University of North Carolina at Chapel Hill School of Medicine researcher.

The phase III trial included 646 patients from 18 countries with relapsed or refractory multiple myeloma, a condition in which cancerous cells continue to multiply despite treatment. Patients in the trial were randomly assigned to receive the drug bortezomib (Velcade), standard therapy for relapsed multiple myeloma, or a combination of Velcade and Doxil, a chemotherapy drug (doxorubicin) delivered via liposomes, or microscopic fat bubbles.

An interim analysis of study participants who received the combination treatment showed a better response in the combination group than in participants who received standard treatment. The combination group's median time to progression - the time interval between the response to treatment and the time the disease starts to show evidence of growing or recurring - was 9.3 months, while those on Velcade alone progressed after 6.5 months.

The three-month improvement is an important step forward in treatment for multiple myeloma, said Dr. Robert Orlowski, Lenvel Lee Rothrock associate professor in the department of hematology/oncology at the School of Medicine, and a member of the UNC Lineberger Comprehensive Cancer Center.

Orlowski presented the trial's early results on Monday (Dec. 11), at the meeting of the American Society of Hematology in Orlando, Fla. The study was supported by Johnson & Johnson, which owns Ortho Biotech, the maker of Doxil, and also has a financial interest in Velcade.

"The data for time to progression were so positive and encouraging that we decided to announce this information earlier than anticipated so more people could be aware of the benefits of this combination,

Contact: L. H. Lang
University of North Carolina School of Medicine

Page: 1 2

Related medicine news :

1. Phase II study shows combination improves survival of metastatic melanoma patients
2. Certain combination therapy found more effective for treating malaria in African children
3. To get blood pressure under control, combination of medicines may be best
4. Drug/intervention combinations offer benefit in severe CVD
5. Scripps research combination therapy obliterates new vessel growth in tumors and retinopathy
6. Drug combination proves effective against myeloma in Phase I trial
7. Drug combination could reduce risk of severe asthma attacks
8. Transplant patients keep their new kidney longer with a CellCept-based drug combination
9. Rheumatoid arthritis patients can benefit from Enbrel in combination with methotrexate
10. New combination therapy after surgery improves survival for pancreatic cancer patients
11. International study launched testing new drug combination to cut cardiovascular disease

Post Your Comments:

(Date:9/3/2020)... ... September 03, 2020 , ... The growing ... focus of Fall 2020 Virtual Conference, a two-day virtual event for radiology professionals ... & Beyond" is the follow-up to AuntMinnie.com's successful virtual event in spring 2020, ...
(Date:9/2/2020)... (PRWEB) , ... September 02, 2020 , ... ... enterprise software for healthcare payers administering Medicare Advantage and Special Needs plans, is ... presented by America’s Health Insurance Plans (AHIP). RAM is supporting the event as ...
(Date:9/1/2020)... Calif. (PRWEB) , ... September 01, 2020 , ... As ... “safe side”, the Cohn Health Institute has taken this time to expand ... celebration of its 30th Anniversary, the Cohn Health Institute will be relaunching its brand ...
(Date:8/31/2020)... ... August 31, 2020 , ... Just found out your dear friend has cancer? , ... your friend or family member shares their diagnosis. Once the shock wears off, the questions ... wrong thing? What are the best ways to help? Words are failing me. I’m scared. ...
(Date:8/31/2020)... ... August 31, 2020 , ... Colorado State University Global ... and affordable online education – is proud to announce its new master’s degree ... of its kind in the nation, the 60-credit hour program is designed to ...
Breaking Medicine News(10 mins):
(Date:9/1/2020)... ... September 01, 2020 , ... Breast and ovarian cancers are common diseases that ... of breast cancers (about 7,500 women per year) and 10% of ovarian cancers (about ... Both genes are detectable in the Women’s Excellence Genetic Testing Program. , Dr. ...
(Date:8/31/2020)... ... 2020 , ... Continuing on its rapid national expansion - ... deodorization provider - is proud to announce it has opened doors in Phoenix, ... residents throughout the area. , Germinator provides a 100% safe and non-toxic sanitizing ...
(Date:8/28/2020)... ... 28, 2020 , ... Dr. Raheleh Sarbaziha has been reimagining ... approach. Armed with her qualifications from Ross University School of Medicine and the ... human body with the nation and world. With a fellowship in Integrative Medicine ...
Breaking Medicine Technology:
Cached News: